Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-13T22:48:25.042Z Has data issue: false hasContentIssue false
  • English
  • Français

Exploring the Application of Cost-Effectiveness Evaluation in the Japanese National Health Insurance System

Published online by Cambridge University Press:  21 March 2019

Hisayuki Ogura ,
Shigekazu Komoto ,
Takeru Shiroiwa  and
Takashi Fukuda
Hisayuki Ogura*
Affiliation:
Medical Economics Division, Health Insurance Bureau, Ministry of Health, Labour and Welfare, Tokyo, Japan
Shigekazu Komoto
Affiliation:
Medical Economics Division, Health Insurance Bureau, Ministry of Health, Labour and Welfare, Tokyo, Japan
Takeru Shiroiwa
Affiliation:
National Institute of Public Health, Saitama, Japan
Takashi Fukuda
Affiliation:
National Institute of Public Health, Saitama, Japan
*
Author for correspondence: Hisayuki Ogura, E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives

Advances in health care due to the development and introduction of new drugs and medical devices have brought considerable benefits to people and patients in terms of upgraded quality of life and extended years of survival. However, some are concerned that the very advancement of health care would increase further the inflation of national healthcare costs. In response to these concerns, Japan's Central Social Insurance Medical Council (“Chuikyo”) began in 2012 to examine how cost-effectiveness evaluation might be applied to the national health insurance system, and has been working toward establishing a system for its usage.

Methods

Cost-effectiveness evaluation was adopted on a trial basis in fiscal year (FY) 2016, targeting seven drugs and six medical devices. Analyses and re-analyses were performed by manufacturers and a public expert organization, respectively. Based on these analyses, a cost-effectiveness evaluation expert organization conducted an overall assessment (“appraisal”). Results of the evaluation were used to adjust the prices of the target items.

Results

Following the trial adoption of cost-effectiveness evaluation, price adjustments were performed for three items in April 2018. Meanwhile, a decision was also made to examine seven items for which technical requirements were identified due to differences in the understanding of analysis methods between involved parties.

Conclusions

The Chuikyo will examine how to meet the newly identified technical requirements and discuss specific details with regard to establishing a system that incorporates cost-effectiveness evaluation. The Chuikyo plans to reach a conclusion by the end of FY 2018.

Keywords

Medical economics evaluationMedical technology evaluationCost-effectiveness evaluationCentral Social Insurance Medical Council
Type
Theme Submission
Information
International Journal of Technology Assessment in Health Care , Volume 35 , Issue 6 , 2019 , pp. 452 - 460
Copyright
Copyright © Cambridge University Press 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Factor Analysis of Increase in Health Care Costs (336th Plenary Session of the Central Social Insurance Medical Council) [Japanese]. Tokyo: Ministry of Health, Labour and Welfare; 2016. http://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000137953.pdf.Google Scholar
2.Standard for Drug Price Calculation (Revision of Medical Fees FY2016) (Notification from the Director-General of the Health Insurance Bureau) [Japanese]. Tokyo: Ministry of Health, Labour and Welfare; 2016. https://www.mhlw.go.jp/file/06-Seisakujouhou-12400000-Hokenkyoku/0000112492.pdf.Google Scholar
3.Standard for Insurance Reimbursement Price Calculation for Special Treatment Materials (Revision of Medical Fees FY2016) (Notification from the Director-General of the Health Insurance Bureau) [Japanese]. Tokyo: Ministry of Health, Labour and Welfare; 2016. https://www.mhlw.go.jp/file/06-Seisakujouhou-12400000-Hokenkyoku/0000112351.pdf.Google Scholar
4.Status Survey Report concerning the Implementation of Cost-Effectiveness Evaluation in Foreign Countries FY2017 (MHLW Effectiveness Evaluation Promotional Project for the Expedited Appropriate Assessment of State-of-the Art Medical Technologies) Tokyo: Ministry of Health, Labour and Welfare; 2018.Google Scholar
5.Draft Interim Classification of Discussions (14th Session of the Special Committee on Cost-Effectiveness Evaluation) [Japanese]. Tokyo: Ministry of Health, Labour and Welfare; 2013. http://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000029639.pdf.Google Scholar
6.Draft Planned Course for the Special Committee on Cost-Effectiveness Evaluation (16th Session of the Special Committee on Cost-Effectiveness Evaluation) [Japanese]. Tokyo: Ministry of Health, Labour and Welfare; 2014. https://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000044417.pdf.Google Scholar
7.Examination Using Specific Examples (17th Session of the Special Committee on Cost-Effectiveness Evaluation) [Japanese]. Tokyo: Ministry of Health, Labour and Welfare; 2014. https://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000047063.pdf.Google Scholar
8.Basic Policy on Economic and Fiscal Management and Reform 2015 - Without economic revitalization, there can be no fiscal consolidation. Tokyo: Cabinet Office; 2015. http://www5.cao.go.jp/keizai-shimon/kaigi/cabinet/2015/2015_basicpolicies_en.pdf.Google Scholar
9.Draft Preparation of Notifications concerning the Trial adoption of Cost-Effectiveness Evaluation (32nd Session of the Special Committee on Cost-Effectiveness Evaluation) [Japanese]. Tokyo: Ministry of Health, Labour and Welfare; 2016. https://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000107178.pdf.Google Scholar
10.Handling of Cost-Effectiveness Evaluation for Drugs and Medical Devices (Revision of Medical Fees FY2016) (Notification from the Director-General of the Health Policy Bureau and the Director-General of the Health Insurance Bureau, MHLW) [Japanese]. Tokyo: Ministry of Health, Labour and Welfare; 2016. https://www.mhlw.go.jp/file/06-Seisakujouhou-12400000-Hokenkyoku/0000112354.pdf.Google Scholar
11.Draft Target Items for the Trial Adoption of Cost-Effectiveness Evaluation (34th Session of the Special Committee on Cost-Effectiveness Evaluation) [Japanese]. Tokyo: Ministry of Health, Labour and Welfare; 2016. http://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000122982.pdf.Google Scholar
12.Analysis Guidelines for Cost-Effectiveness Evaluation at the Central Social Insurance Medical Council (33rd Session of the Special Committee on Cost-Effectiveness Evaluation) [Japanese]. Tokyo: Ministry of Health, Labour and Welfare; 2016. http://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000109789.pdf.Google Scholar
13.Assessment Results of the 13 Target Items in the Trial Adoption (7th Joint Session of the Special Committee on Cost-Effectiveness Evaluation, the Special Committee on Drug Price, and the Special Treatment Material Expert Committee) [Japanese]. Tokyo: Ministry of Health, Labour and Welfare; 2017. https://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000196682.pdf.Google Scholar
14.Handling of Requirements in the Trial Adoption of Cost-Effectiveness Evaluation (Other Issues) (5th Joint Session of the Special Committee on Cost-Effectiveness Evaluation, the Special Committee on Drug Price, and the Special Treatment Material Expert Committee) [Japanese]. Tokyo: Ministry of Health, Labour and Welfare; 2017. https://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000184180.pdf.Google Scholar
15.Fundamental Reform in the Drug Price System (140th Session of the Special Committee on Drug Price) [Japanese]. Tokyo: Ministry of Health, Labour and Welfare; 2017. https://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000188612.pdf.Google Scholar
16.Examination for the Review of Special Treatment Material System (87th Session of the Special Treatment Material Expert Committee) [Japanese]. Tokyo: Ministry of Health, Labour and Welfare; 2017. https://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000185633.pdf.Google Scholar
17.Present Status and Handling of Requirements in the Trial Adoption of Cost-Effectiveness Evaluation (6th Joint Session of the Special Committee on Cost-Effectiveness Evaluation, the Special Committee on Drug Price, and the Special Committee on Insurance Medical Material) [Japanese]. Tokyo: Ministry of Health, Labour and Welfare; 2017. http://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000184179.pdf.Google Scholar
18.Results of Price Adjustment Based on the Results of Cost-Effectiveness Evaluation (7th Joint Session of the Special Committee on Cost-Effectiveness Evaluation, the Special Committee on Drug Price, and the Special Treatment Material Expert Committee) [Japanese]. Tokyo: Ministry of Health, Labour and Welfare; 2017. https://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000196683.pdf.Google Scholar
19.Draft Planned Course for Cost-Effectiveness Evaluation (7th Joint Session of the Special Committee on Cost-Effectiveness Evaluation, the Special Committee on Drug Price, and the Special Treatment Material Expert Committee) [Japanese]. Tokyo: Ministry of Health, Labour and Welfare; 2017. https://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000196684.pdf.Google Scholar
20.Examination toward Trial Adoption (No. 2) (30th Session of the Special Committee on Cost-Effectiveness Evaluation) [Japanese]. Tokyo: Ministry of Health, Labour and Welfare; 2015. https://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000104721.pdf.Google Scholar
21.Draft Summary of Discussions to Date toward the Establishment of a Cost-Effectiveness Evaluation System (43rd Session of the Special Committee on Cost-Effectiveness Evaluation) [Japanese]. Tokyo: Ministry of Health, Labour and Welfare; 2017. https://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000170913.pdf.Google Scholar
22.WHO Commission on Macroeconomics and Health. Macroeconomics and health: Investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: WHO; 2001. http://www1.worldbank.org/publicsector/pe/PEAMMarch2005/CMHReport.pdf.Google Scholar
23.The National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. London: NICE; 2013. https://www.nice.org.uk/process/pmg9.Google Scholar
Supplementary material: File

Ogura et al. supplementary material

Ogura et al. supplementary material
Download Ogura et al. supplementary material(File)
File 88 KB